Latest news and insights on the pharmaceutical industry | Indian Pharma Post

Results For "ENSPRYNG"

2 News Found

ENSPRYNG cuts MOGAD relapse risk by 68% in landmark Phase III trial: Roche
Clinical Trials | April 22, 2026

ENSPRYNG cuts MOGAD relapse risk by 68% in landmark Phase III trial: Roche

The Phase III METEOROID study met its primary endpoint, with ENSPRYNG cutting the risk of a first relapse by 68% compared to placebo in adults and adolescents

Roche to present data across neuroscience portfolio at 2022 AAN Annual Meeting
News | March 25, 2022

Roche to present data across neuroscience portfolio at 2022 AAN Annual Meeting

Additional data across neurological disorders, including Alzheimer’s disease, help advance the scientific understanding of these conditions and the potential impact of early treatment

Latest Stories

Crown Bioscience partners with Turbine to accelerate translational oncology research

ProBioGen appoints Dr Simon Johannes Bulling as its new Chief Operating Officer

New brain study reveals why alcohol relapse remains a persistent challenge

White Papers

Chasing Consistency: Centralizing operations data is the key to optimizing chemicals plants

Implementing a digital transformation in chemical operations to maximize profitability

The complexity of compliance

The Sprint to the Summit: Unlocking Lab Efficiency through Digital Transformation

The guiding role of fluidized and spouted bed technologies in particle building processes

Interviews
We believe in trust-driven clinical conversations to cut through medical misinformation: Saurav Kasera, Founder, CLIRNET
We believe in trust-driven clinical conversations to cut through medical misinformation: Saurav Kasera, Founder, CLIRNET
Saurav Kasera Founder, CLIRNET
Only 4-5 Indian pharma companies have a strong presence in Russia, opportunity is far bigger now: Manish Kumar, Vice-Chairman, Moscow Chamber of Commerce, Indian Commission; and President, Soltex Group
Only 4-5 Indian pharma companies have a strong presence in Russia, opportunity is far bigger now: Manish Kumar, Vice-Chairman, Moscow Chamber of Commerce, Indian Commission; and President, Soltex Group
Only 4-5 Indian pharma companies have a strong presence in Russia but the opportunity is far bigger now: Manish Kumar, Vice-Chairman, Moscow Chamber of Commerce, Indian Commission; and President, Soltex Group
Only 4-5 Indian pharma companies have a strong presence in Russia but the opportunity is far bigger now: Manish Kumar, Vice-Chairman, Moscow Chamber of Commerce, Indian Commission; and President, Soltex Group

Packaging